Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity

Clifford R. Jack, Heather J. Wiste, Stephen D. Weigand, David S. Knopman, Val Lowe, Prashanthi Vemuri, Michelle M. Mielke, David T. Jones, Matthew L. Senjem, Jeffrey L. Gunter, Brian E. Gregg, Vernon S. Pankratz, Ronald C. Petersen

Research output: Contribution to journalArticle

128 Scopus citations

Abstract

Objective: To estimate the incidence of and to characterize cognitive and imaging findings associated with incident amyloid PET positivity. Methods: Cognitively normal (CN) participants in the Mayo Clinic Study of Aging who had 2 or more serial imaging assessments, which included amyloid PET, FDG-PET, and MRI at each time point, were eligible for analysis (n 5 207). Twelve subjects with Alzheimer disease dementia were included for comparison. Results: Of the 123 CN participants who were amyloid-negative at baseline, 26 met criteria for incident amyloid PET positivity. Compared to the 69 subjects who remained stable amyloid-negative, on average these 26 did not differ on any imaging, demographic, or cognitive variables except amyloid PET (by definition) and task-free functional connectivity, which at baseline was greater in the incident amyloid-positive group. Eleven of the 26 incident amyloid-positive subjects had abnormal hippocampal volume, FDG-PET, or both at baseline. Conclusions: The incidence of amyloid PET positivity is approximately 13% per year among CN participants over age 70 sampled from a population-based cohort. In 15/26 (58%), incident amyloid positivity occurred prior to abnormalities in FDG-PET and hippocampal volume. However, 11/26 (42%) incident amyloid-positive subjects had evidence of neurodegeneration prior to incident amyloid positivity. These 11 could be subjects with combinations of preexisting non-Alzheimer pathophysiologies and tau-mediated neurodegeneration who newly entered the amyloid pathway. Our findings suggest that both "amyloid-first" and "neurodegeneration-first" biomarker profile pathways to preclinical AD exist.

Original languageEnglish (US)
Pages (from-to)1732-1740
Number of pages9
JournalNeurology
Volume81
Issue number20
DOIs
StatePublished - Nov 12 2013

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity'. Together they form a unique fingerprint.

  • Cite this